Paula L. Croal

Paula L. Croal

Auto-generated profile, based on publicly available information

Paula L. Croal

Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MSMichael Skwarski
Michael Skwarski
DMDaniel McGowan
Daniel McGowan
EBElizabeth Belcher
Elizabeth Belcher
FCFrancesco Di Chiara
Francesco Di Chiara
DSDionisios Stavroulias
Dionisios Stavroulias
GHGeoff S. Higgins
Geoff S. Higgins
Purpose: Tumor hypoxia fuels an aggressive tumor phenotype and confers resistance to anticancer treatments. We conducted a clinical trial to determine whether the antimalarial drug atovaquone, a known mitochondrial inhibitor, reduces hypoxia in non–small cell lung cancer (NSCLC). Patients and Methods: Patients with NSCLC scheduled for surgery were recruited sequentially into two cohorts: cohort 1 received oral atovaquone at the standard clinical dose of 750 mg twice daily, while cohort 2 did not. Primary imaging endpoint was change in tumor hypoxic volume (HV) measured by hypoxia PET-CT. Intercohort comparison of hypoxia gene expression signatures using RNA sequencing from resected tumors was performed. Results: Thirty patients were evaluable for hypoxia PET-CT analysis, 15 per cohort. Median treatment duration was 12 days. Eleven (73.3%) atovaquone-treated patients had meaningful HV reduction, with median change −28% [95% confidence interval (CI), −58.2 to −4.4]. In contrast, median change in untreated patients was +15.5% (95% CI, −6.5 to 35.5). Linear regression estimated the expected mean HV was 55% (95% CI, 24%–74%) lower in cohort 1 compared with cohort 2 (P = 0.004), adjusting for cohort, tumor volume, and baseline HV. A key pharmacodynamics endpoint was reduction in hypoxia-regulated genes, which were significantly downregulated in atovaquone-treated tumors. Data from multiple additional measures of tumor hypoxia and perfusion are presented. No atovaquone-related adverse events were reported. Conclusions: This is the first clinical evidence that targeting tumor mitochondrial metabolism can reduce hypoxia and produce relevant antitumor effects at the mRNA level. Repurposing atovaquone for this purpose may improve treatment outcomes for NSCLC.

1 December 2016 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
PKPrzemyslaw D. Kosinski
Przemyslaw D. Kosinski
PCPaula L. Croal
Paula L. Croal
JLJackie Leung
Jackie Leung
SWSuzan Williams
Suzan Williams
IOIsaac Odame
Isaac Odame
AKAndrea Kassner
Andrea Kassner

17 March 2016 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
JLJackie Leung
Jackie Leung
PKPrzemyslaw D. Kosinski
Przemyslaw D. Kosinski
PCPaula L. Croal
Paula L. Croal
AKAndrea Kassner
Andrea Kassner

1 October 2011 in NeuroImage
Verified
Journal Article
Closed access
EHEmma L. Hall
Emma L. Hall
IDIan D. Driver
Ian D. Driver
PCPaula L. Croal
Paula L. Croal
SFSusan Francis
Susan Francis
PGPenny A. Gowland
Penny A. Gowland
MBMatthew J. Brookes
Matthew J. Brookes

1 February 2019 in NeuroImage
Verified
Journal Article
Closed access
MBMolly G. Bright
Molly G. Bright
PCPaula L. Croal
Paula L. Croal
NBNicholas Blockley
Nicholas Blockley
DBDaniel P. Bulte
Daniel P. Bulte

1 January 2015 in NeuroImage
Verified
Journal Article
Closed access
PCPaula L. Croal
Paula L. Croal
EHEmma L. Hall
Emma L. Hall
IDIan D. Driver
Ian D. Driver
MBMatthew J. Brookes
Matthew J. Brookes
PGPenny A. Gowland
Penny A. Gowland
SFSusan Francis
Susan Francis